Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance

Summary

The purpose of the study is to see if tumors respond to endocrine therapy by taking a total of 21 doses of Tamoxifen before and after surgery. Tamoxifen is currently approved by the FDA (Food and Drug Administration) for use in the treatment of hormone positive breast cancer.

Timeline

Start

2012-08

Primary completion

2016-11

Completion

2016-11

Outcome

Met primary endpoint

registry MEAN Tamoxifen Pre and Post Breast Surgery: -40 (-63 to -29) percentage change in Ki67 NCT01614210 ↗

registry analysis (other test); Tamoxifen Pre and Post Breast Surgery; p = 0.0001; t-test, 1 sided NCT01614210 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Tamoxifen	Small molecule	20 mg	Oral

Indications